NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · MLND · USD
Stock price
Quote as of Jun 28, 2021, 04:00 AM UTC. Cached market data; not a live quote.
Price history is currently unavailable.
Millendo Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 6.19% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Millendo Therapeutics, Inc. is an advanced biopharmaceutical firm dedicated to developing innovative therapies for rare hormonal disorders, primarily within the United States. The company's key therapeutic candidates include livoletide, an investigational drug aimed at Prader-Willi syndrome; nevanimibe, an experimental compound designed for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist intended to alleviate vasomotor symptoms (such as hot flashes) in women experiencing menopause. This enterprise maintains its primary operational base in Ann Arbor, Michigan.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:07 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$14.20+$0.34 (+2.45%)
Korro Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.74% below the high.
$2.06+$0.07 (+3.52%)
TuHURA Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 39.94% below the high.
$0.26-$0.01 (-3.13%)
Applied Molecular Transport Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.69% below the high.
$0.10$0.00 (0.0%)
ObsEva S.A.’s quoted price sits in the lower half of its reported 52-week range, 95.24% below the high.
$6.37-$0.41 (-5.98%)
Cyclacel Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.93% below the high.
$0.25-$0.09 (-27.68%)
Notable Labs, Ltd.’s quoted price sits in the lower half of its reported 52-week range, 94.15% below the high.
